TREMFYA (guselkumab) Demonstrates a Differentiated Binding Mechanism from Risankizumab in In Vitro Studies - MyChesCo
SPRING HOUSE, PA — The Janssen Pharmaceutical Companies of Johnson & Johnson recently announced additional results from in vitro MODIF-Y studies, which continue to support a hypothesis that not all IL-23 …
MyChesCo
